SELLAS Life Sciences Group, Inc. (FRA:RXK3)

Market Cap	286.88M
Revenue (ttm)	n/a
Net Income (ttm)	-22.11M
Shares Out	n/a
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,600
Average Volume	3,797
Open	1.948
Previous Close	1.786
Day's Range	1.948 - 2.040
52-Week Range	0.801 - 2.600
Beta	n/a
RSI	71.19
Earnings Date	Mar 18, 2026

About FRA:RXK3

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Angelos Stergiou
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RXK3

Financial Performance

Financial numbers in USD